• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

更正：一项随机、开放标签、平行、多中心IV期研究，旨在比较阿托伐他汀10毫克和20毫克在高危亚洲高胆固醇血症患者中的疗效和安全性。

Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.

作者信息

Kim Ji Bak, Song Woo Hyuk, Park Jong Sung, Youn Tae-Jin, Park Yong Hyun, Kim Shin-Jae, Ahn Sung Gyun, Doh Joon-Hyung, Cho Yun-Hyeong, Kim Jin Won

出版信息

PLoS One. 2021 Oct 20;16(10):e0259072. doi: 10.1371/journal.pone.0259072. eCollection 2021.

DOI:10.1371/journal.pone.0259072
PMID:34669740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8528292/
Abstract

[This corrects the article DOI: 10.1371/journal.pone.0245481.].

摘要

[本文更正了文章的数字对象标识符：10.1371/journal.pone.0245481。]

相似文献

1
Correction: A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.更正：一项随机、开放标签、平行、多中心IV期研究，旨在比较阿托伐他汀10毫克和20毫克在高危亚洲高胆固醇血症患者中的疗效和安全性。
PLoS One. 2021 Oct 20;16(10):e0259072. doi: 10.1371/journal.pone.0259072. eCollection 2021.
2
Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia.依折麦布与阿托伐他汀联合应用于日本高胆固醇血症患者的临床疗效及耐受性——依折麦布在高胆固醇血症患者中的IV期随机对照试验
Curr Ther Res Clin Exp. 2012 Feb;73(1-2):16-40. doi: 10.1016/j.curtheres.2012.02.002.
3
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.瑞舒伐他汀10毫克/天与阿托伐他汀10毫克/天对高危成年人影响的12周多中心随机开放标签比较：一项探索性研究
Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015.
4
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.在重度高胆固醇血症高危患者中实现脂蛋白目标：依折麦布与阿托伐他汀联合应用的疗效和安全性。
Am Heart J. 2004 Sep;148(3):447-55. doi: 10.1016/j.ahj.2004.03.052.
5
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).一项比较瑞舒伐他汀与阿托伐他汀在亚洲心血管疾病高危患者临床实践中实现血脂目标的疗效和安全性的随机研究（DISCOVERY-亚洲研究）。
Curr Med Res Opin. 2007 Dec;23(12):3055-68. doi: 10.1185/030079907x242809.
6
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.比较低剂量匹伐他汀与阿托伐他汀在高胆固醇血症患者中的疗效和安全性。
Ann Pharmacother. 2010 Mar;44(3):415-23. doi: 10.1345/aph.1M522. Epub 2010 Feb 23.
7
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.匹伐他汀与阿托伐他汀的疗效和耐受性比较：一项针对韩国高胆固醇血症患者的为期8周的多中心、随机、开放标签、剂量滴定研究。
Clin Ther. 2007 Nov;29(11):2365-73. doi: 10.1016/j.clinthera.2007.11.002.
8
Pitavastatin - results from phase III & IV.匹伐他汀——III期和IV期试验结果。
Atheroscler Suppl. 2010 Dec;11(3):8-14. doi: 10.1016/S1567-5688(10)71064-3.
9
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.低剂量阿托伐他汀和瑞舒伐他汀对血浆脂质谱的影响：一项针对原发性高胆固醇血症患者的长期、随机、开放标签研究。
Am J Cardiovasc Drugs. 2008;8(4):265-70. doi: 10.2165/00129784-200808040-00006.
10
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.使用他汀类药物对高危患者进行强化降脂治疗的卓越益处：斯巴鲁研究——与阿托伐他汀治疗相比，更多高胆固醇血症患者通过瑞舒伐他汀治疗达到日本动脉粥样硬化协会的低密度脂蛋白胆固醇目标。
J Atheroscler Thromb. 2008 Dec;15(6):314-23. doi: 10.5551/jat.e567. Epub 2008 Dec 6.

引用本文的文献

1
Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.在斯里兰卡急性冠状动脉综合征队列中，40毫克与80毫克阿托伐他汀的疗效、安全性和成本效益：一项单中心随机对照临床试验方案。
Trials. 2025 Sep 1;26(1):326. doi: 10.1186/s13063-025-08943-2.

本文引用的文献

1
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.一项随机、开放标签、平行、多中心的 IV 期研究，旨在比较阿托伐他汀 10 毫克和 20 毫克在高胆固醇血症的高危亚洲患者中的疗效和安全性。
PLoS One. 2021 Jan 22;16(1):e0245481. doi: 10.1371/journal.pone.0245481. eCollection 2021.